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C E L E S T
F A C U L T Y  O F  L AW ,  U N I V E R S I T Y  O F  M A L A Y A
C E N T R E  F O R  L AW  A N D  E T H I C S  I N  S C I E N C E  A N D  T E C H N O L O G Y
The Centre for Law and Ethics in Science
and Technology (CELEST) is a research
centre at the Faculty of Law, University of
Malaya. CELEST was previously known as
the Centre of Excellence for Biodiversity
Law (CEBLAW). This renaming initiative,
which took place in 2017, was prompted
by the transformative impact of rapid
developments in science and technology
on our daily lives and, more generally,
the world around us. CELEST engages in
and promotes research on the legal and
ethical implications of the broad field of
science and technology. 
Given the revolutionary technological
changes that are taking place, it is
crucial to understand how science and
technology interact with and challenge
the norms and standards which we are
all too familiar with. The areas of
research which CELEST is interested in
includes biodiversity law, cyberlaw, data
protection law, energy law,
environmental law, law of the sea, media
law, health law and nanotechnology law.
Welcome to Our 
Inaugural Newsletter! 
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On a wider front, CELEST is keen to
explore and better understand the
emerging issues that arise from the
intersection between law and ethics with
science and technology. In this regard,
CELEST welcomes research
collaborations in these fields to further
the discourse between the
developments in science and technology
and the law as well as ethics. 
CELEST is proud to present this inaugural
newsletter to introduce the Centre. We
hope this newsletter will encourage
discussion on contemporary issues on
the integration of law and ethics with
science and technology. In this issue, we
bring to you a brief write-up of a research
currently undertaken by our researcher
and academic staff at the Faculty of Law,
Dr Mohammad Firdaus Abdul Aziz,
which discusses ethical, legal and
governance issues of biobanking. 
We hope that you will enjoy reading it! 
Tay Pek San, PhD 
Associate Professor  
Faculty of Law 
University of Malaya 
Director of CELEST 
Editor: Ainee Adam, PhD 
Disclaimer: The views expressed in this Newsletter are not necessarily the views of CELEST 
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‘Biobanking’, also known as ‘biorepositories’
and ‘genetic databases’, is widely regarded
as an important means to facilitate
biomedical research. It functions as
repositories of human biological samples.
The Council of Europe has offered a
definition of ‘biobanking’ as: “the collection
of biological materials which has a
population basis; it is established to supply
biological materials or data for multiple
future research projects, contains biological
materials and associated personal data that
may include or may be linked to
genealogical, medical and lifestyle data; it
may be regularly updated and receives  
and supplies materials in an organized 
manner.” 
In general, there are two types of biobanks,
categorised based on the purpose of its
establishment and the types of samples
collected namely (i) disease-specific-based
biobanks that collect specific samples from
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 conditions and (ii) population-based
biobanks that collect different types of
samples from large numbers of people
with or without medical conditions.  
Researchers would be able to use the
deposited samples to carry out
biomedical research on various human
health issues and diseases. Such
research is crucial to help patients with
rare diseases whose medical needs are
unmet by today’s medicine and to
address widely spread diseases. It could
also contribute towards the discovery of
new genes that are responsible for
genetic diseases, which means this
could even lead to medical care and
treatment tailored specifically to
individual needs (also known as
‘personalised medicine’).   
Given the benefits, there are many
biobanks that have been established
across the globe - European Biobanks,
North American Biobanks, Asian
Biobanks, Australian Biobanks, and
Middle East Biobanks.   Some of the
notably largest biobanks in the world
store samples collected from half a
million of individuals or more, such as
the UK Biobank, “All of Us” Biobank in
the US, and Shanghai Zhangjiang
Biobank.   
In order to leverage on the collected
samples to accelerate and further
increase laboratory discoveries, some
biobanks create network between them.
Such approach would facilitate
collaboration among local and foreign 
researchers, as well as enable flow of 
information and knowledge between
the networks. For instance, the
Biobanking and Biomolecular  
Resources Research Infrastructure
(BBMRI) was created in 2008 
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What is Biobanking? 
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to bring all existing biobanks in Europe
together to make high quality biological
resources available for human health
research across the continent. 
Malaysia also plays an important role in this
global effort to combat human health
issues by establishing its own national
biobank known as The Malaysian Cohort
Project. It is an initiative by the government
in 2005, set up through the then Ministry of
Science, Technology and Innovation
(MOSTI), coordinated by the Malaysian
Genome Institute and led by the UKM
Medical Molecular Biology Institute (UMBI).
 It is part of the Asia Cohort Consortium, a
network of population-based biobanks
across the Asian jurisdictions namely
Bangladesh, China, India, Japan, Korea,
Mongolia, Singapore, and Taiwan.  Primarily,
the Project  aims to improve the approach
taken in preventing as well as to improve
the treatment and diagnosis of major
diseases that have been identified in
Malaysia. 
In so doing, more than 100,000 participants
aged between 35 and 65 from various
socioeconomic groups from all over the
country were recruited. This can be
considered as the biggest and most
comprehensive cohort study in Malaysia, 
storing the largest number of human
samples in the country, thus providing
valuable resource for epidemiological and
biomedical research. 
... there is an issue relating to the privacy and
confidentiality of personal information and data
linked to the samples collected (associated data).
There are concerns that there may be misuse of
personal information and associated data, as this
could also be used to trace the individual’s family
genetic information and private life.  
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Aside from the Malaysian Cohort Project,
Malaysia has a number of Assisted
Reproductive Technology (ART) clinics
that can be considered as biobanks.
Based on the data published by the
Malaysian Society for Assisted
Reproductive Technology, there are 17
ART clinics in the country that provide
treatment and carry out research as well
as storage program donors for sperm,
eggs and embryos.  In addition, a general
search on Google map indicates that
there are 19 other ART clinics in Malaysia. 
There are also tissue-specific-based
biobanks that store certain types of
human tissues (i.e. blood) in Malaysia
such as Cellsafe International (Malaysia)
Sdn. Bhd., Cryocord Sdn. Bhd., and
StemLife Berhad. University of Malaya
itself has also established a number of
biobanks to store specific tissues such as
the Malaysian Periodontal Database and
Biobank System and Malaysian Oral
Cancer Database and Tissue Bank
System.  
Notwithstanding the promising benefits,
there is a myriad of complex ethical and
legal issues surrounding this area, some
of which are briefly discussed here. 
First, there is an issue relating to the
privacy and confidentiality of personal
information and data linked to the
samples collected (associated data).
There are concerns that there may be
misuse of personal information and
associated data, as this could also be
used to trace the individual’s family
genetic information and private life. Any
misconduct and mishandling of the data
could have an adverse effect on this field
and impact on public trust. 
Biobanking in Malaysia
Ethical and Legal Issues of Biobanking
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Second, as human subjects are involved,
informed consent is an essential tool to
ensure ethical conduct and to protect
them. Its application has been debated
extensively in terms of which model of
consent (i.e. broad consent, specific
consent, meta-consent, dynamic
consent) would be appropriate and it is
still yet to be resolved. 
Third, there is an issue about ownership
of the samples and data collected. A
survey shows that even though most
sample donors believed that research
institutions are the owners of the
samples collected, they indicated that
they have the right to decide what
would be done to their donated
samples.  This could pose a problem
when samples are shared and
transferred to another institution. How
would the ‘custodian’ biobanks know
exactly what happen to the transferred
samples?  
Fourth, there are also issues with
commercial activities such as
commercialisation of biobanks resources
(samples and data) or products derived
from research using the resources,
private investment in public biobanks, or
private funding of biobanks.  Previous
studies have shown that public trust in
biobanks and biobank research
decreases significantly if commercial
actors are involved.  Samples donor also
expressed concern of the possibility of
losing control over their samples if
research work involved for-profit
companies. Also, researchers may gain
personal recognition and financial
benefits through commercialisation,
which could violate the interests of
research participants. 
Due to the abovementioned ethical
issues, many countries have introduced  
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rules to regulate biobanks and they vary
from one country to another. A recent  
study has shown that different biobanks
adopt different regulatory approaches,
for instance, accessibility policies  and
such regulatory environment can be
viewed as the greatest barrier to
collaboration and sample sharing,
undermining the acceleration of
scientific discoveries. Therefore,
international scholars have been
discussing the need to harmonise and
standardise regulation of biobanking at
the global level.  This is particularly vital
to facilitate samples and data sharing
between individual biobanks. 
Currently, Malaysia has yet to introduce
specific legislation to govern biobanking.
However, there are relevant laws such as
the existing Private Healthcare Facilities
and Services Act 1998 and Human Tissue
Act 1974 which function as umbrella
Acts for all healthcare services and
facilities in the country. Therefore, ART
clinics that function as biobanks fall
within the ambit of these Acts. The
Ministry of Health has published
Standards for Assisted Reproductive
Technology (ART) Facility in 2012 and
the National Committee for Clinical
Research has introduced Guidelines on
the Use of Human Biological Tissues for
Research 2006. These documents act
merely as guidelines and therefore, not
legally binding. It highlights the
requirement of informed consent,
whereby it requires a written and signed
consent form for any ART procedures
and a separate consent form for
procedures other than treatment such
as cryopreservation and subsequent use
of the surplus embryos and gametes. 
   
Biobank Governance in Malaysia
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The Personal Data Protection Act 2010
is also relevant given the fact that the
collected samples and reproductive  
materials contain sensitive information
that can be traced back to the
individuals. The only regulatory
document that was established
specifically for biobanking would be
the National Standard for Cord Blood
Banking and Transplantation 2008, as
the name implies. Another relevant
guidelines is the National Guidelines
for Stem Cell Research and Therapy
2009 that regulate the use of human
embryos for research purposes as well
as gametes or blastocyst donation. 
Despite the existing regulations, it is
arguable that Malaysia needs to revisit
its regulatory framework for
biobanking to ensure not only that its
approach is in line with the
international regulation, but also to
safeguard local samples. This is
particularly important given the fact
that Malaysian’s biggest biobank is part
of an international network. It has been
argued by scholars that low- and
middle-income countries have weaker
research capacity and governance
mechanisms for biobanks than that of
high-income countries. High-income
countries may see the advantage of
using human samples from low- and
middle-income countries that are rich
with genetic diversity. This will place
low- and middle-income countries at a
risk of exploitation especially if it
concerns benefit sharing. 
   
Despite the existing regulations, it is arguable that
Malaysia needs to revisit its regulatory framework
for biobanking to ensure not only that its
approach is in line with the international
regulation, but also to safeguard local samples.  
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Since Malaysia falls within the category
of low- and middle-income countries, it
would be interesting to find out
Malaysia’s current situation as to
whether or not Malaysia would need to
develop a more robust regulatory
framework. In addition, it can also be
argued that it would be beneficial to
have specific legislation and clear
regulatory regime in place to facilitate
ethical development of biobanking in
Malaysia. In so doing, further research is
needed since currently, there is a lack of
literature on the ethical issues from the
local perspective as well as the
examination of the adequacy of the
current framework. 
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Dr Mohammad Firdaus bin Abdul Aziz obtained
his BSc (Genetics and Molecular Biology) from
the University of Malaya. He was awarded the
National Science Fellowship and furthered his
studies at the University of Sheffield, where he
graduated with MA in Biotechnological Law
and Ethics. Firdaus then pursued his doctorate
at the University of Oxford. His doctoral research
was on improvement to the regulatory
framework for human stem cell research in
Malaysia. He is also interested in exploring
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